Idera Pharmaceuticals, Inc. (IDRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalData
32 Pages - GLDATA50972
$250.00

Summary

Idera Pharmaceuticals, Inc. (Idera) is a clinical stage biotechnology company. It focuses on the discovery, development and commercialization of drug candidates for the treatment of life threatening diseases. It develops DNA and RNA based drug candidates that are targeted against toll-like receptors (TLR) for the treatment of infectious diseases and which can be used as vaccine adjuvants. The company initiated a research program employing its gene silencing oligonucleotides (GSOs), to inhibit the production of disease-associated proteins by targeting RNA. The company designs and formulates proprietary TLR agonists and antagonists to modulate immune responses. The lead product in the pipeline is IMO-8400, an antagonist of TLRs 7, 8, and 9, for the treatment of lupus. The other products in the pipeline comprise vaccine adjuvant, namely, TLR7, TLR 8, and TLR 9 agonists for the treatment of cancer, infectious diseases, and Alzheimer’s disease; and IMO-9200, antagonist of TLRs 7, 8, and 9. Idera is headquartered in Massachusetts, the US.

Idera Pharmaceuticals, Inc. (IDRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Idera Pharmaceuticals, Inc., Medical Devices Deals, 2010 to YTD 2016 9
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Idera Pharma Enters into Research Agreement with University of Texas 11
Licensing Agreements 12
GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 12
Idera Pharma Terminates Licensing Agreement With Merck 13
Equity Offering 15
Idera Pharma Raises USD86.3 Million in Public Offering of Shares 15
Idera Pharma Completes Public Offering Of Common Stock And Pre-Funded Warrants For US$40 Million 17
Idera Pharma Completes Public Offering Of Shares For US$27.7 Million 19
Idera Pharma Completes Public Offering Of Shares And Warrants For US$16.5 Million 21
Idera Pharma Completes Private Placement Of Preferred Shares For US$7 Million 23
Idera Pharma Completes Private Placement Of Convertible Preferred Stock For US$9.5 Million 24
Idera Pharma Files Registration Statement For Public Offering Of US$75 Million 26
Idera Pharma Completes Registered Direct Offering Of US$15 Million 27
Idera Pharmaceuticals, Inc. - Key Competitors 29
Key Employees 30
Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Idera Pharmaceuticals, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Idera Pharmaceuticals, Inc., Medical Devices Deals, 2010 to YTD 2016 9
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Idera Pharma Enters into Research Agreement with University of Texas 11
GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 12
Idera Pharma Terminates Licensing Agreement With Merck 13
Idera Pharma Raises USD86.3 Million in Public Offering of Shares 15
Idera Pharma Completes Public Offering Of Common Stock And Pre-Funded Warrants For US$40 Million 17
Idera Pharma Completes Public Offering Of Shares For US$27.7 Million 19
Idera Pharma Completes Public Offering Of Shares And Warrants For US$16.5 Million 21
Idera Pharma Completes Private Placement Of Preferred Shares For US$7 Million 23
Idera Pharma Completes Private Placement Of Convertible Preferred Stock For US$9.5 Million 24
Idera Pharma Files Registration Statement For Public Offering Of US$75 Million 26
Idera Pharma Completes Registered Direct Offering Of US$15 Million 27
Idera Pharmaceuticals, Inc., Key Competitors 29
Idera Pharmaceuticals, Inc., Key Employees 30

List of Figures
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Idera Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Idera Pharmaceuticals, Inc., Medical Devices Deals, 2010 to YTD 2016 9

$250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838